AMILI is Southeast Asia’s first and only precision gut microbiome company serving as a hub for gut microbiome innovation and therapy. Our aim is to advance microbiome research, grounded in science and compassion, to address unmet and critical needs in healthcare with the potential to positively impact millions of lives across Asia.
United by a shared belief that science can be a powerful driver for the greater good when combined with ethically- and scientifically-backed tools, our cross-disciplinary team is creating a sustainable platform for the collection, processing and distribution of gut microbiome-derived products to hospitals and research institutions.
We are also building the world’s largest multi-ethnic, Asia-centric gut microbiome database to support fundamental discovery into the impact of the gut microbiome on human health in Asia.
As a Singapore-based healthcare organization, we not only leverage the infrastructure and resources of one of Asia’s top biomedical hubs, but also have access to the city’s diverse and global populations to help further purpose-driven science.
DR JEREMY LIM
Vice President, International
Vice President, Growth, Commercials, and Finance
Chief Technology Officer
DR GWENDOLINE TAN
Vice President, Corporate Development
Vice President, Optimisation, People, and Admin
DR SAISHREYAS SUNDARAJOO
Head of Clinical Affairs
KAI YEE TOH
Head of Lab and Research
EMERITUS PROFESSOR DATO’ DR GOH KHEAN LEE
PROFESSOR DR MICHAEL KAMM
ASSOCIATE PROFESSOR DR PISES PISESPONGSA
ADJ. ASSOCIATE PROFESSOR DR RUBEN WONG
ASSOCIATE PROFESSOR LEE YUAN KUN
PROFESSOR DR JOSE SOLLANO
ASSISTANT PROFESSOR DR CHING JIANGHONG
DR CHRISTOPHER TING
At AMILI, we are pushing the boundaries of biomedical science
As one big unconventional family, we embrace diversity as an engine of innovation. Our team is always on the lookout for creative problem solvers, team players and bridge-builders interested in contributing to something greater than themselves. If that sounds like you, we would love to get to know you.